Results 161 to 170 of about 58,906 (283)

Long‐term benefit from adjuvant tamoxifen therapy for ER+ HER2− breast cancer by PR positivity

International Journal of Cancer, Volume 159, Issue 2, Page 450-459, 15 July 2026.
What's new? Tamoxifen is a cornerstone of endocrine therapy for estrogen receptor (ER)‐positive/human epidermal growth factor receptor 2 (HER2)‐negative breast cancer. Its long‐term benefits, however, may vary by progesterone receptor (PR) status. Here, using data from the Stockholm tamoxifen trials, the authors evaluated whether PR expression predicts
Anna E. Nordenskjöld, Magdalena Ríos‐Romero, Huma Dar, Tommy Fornander, Gizeh Perez‐Tenorio, Helena Fohlin, Olle Stål, Julia Tutzauer, Linda S. Lindström   +8 more
wiley   +1 more source

Nodular Vasculitis Following Aromatase Inhibitor Therapy for Breast Cancer: A Case Report. [PDF]

Cureus
Srinivasan S, Jamil M, Tahmazian S, Jamil J, Jabbour-Aida H.   +4 more
europepmc   +1 more source

Systemic anti‐cancer therapy associated with the occurrence of peripheral neurotoxicity and, specifically, peripheral neuropathy

International Journal of Cancer, Volume 159, Issue 2, Page 460-466, 15 July 2026.
What's new? While the effectiveness of systemic anticancer therapy is well documented, it commonly causes severe toxicity. This study of the 467 systemic anticancer therapy agents currently approved globally for clinical and/or research purposes found that peripheral neurotoxicity is associated with 45% of classical chemotherapies, 21% of targeted ...
Cassie Higgins, Lynn R. Gauthier, Blair H. Smith, Lesley Colvin   +3 more
wiley   +1 more source

Lipid and High-Density Lipoprotein (HDL) Subfraction Changes in Premenopausal and Postmenopausal Women With Breast Cancer Receiving Hormonal Therapy. [PDF]

Cureus
Nikolakopoulou A, Nastos K, Papakonstantinou D, Stavrati KE, Michalaki V, Koutroulis G, Dafnios N, Papakonstantinou I, Papadimitriou C.   +8 more
europepmc   +1 more source

FGFR Inhibitor AZD4547 Disrupts Inflammatory CAF Crosstalk With Cancer Cells and Macrophages and Attenuates Metastasis in Pancreatic Cancer

The FASEB Journal, Volume 40, Issue 13, 15 July 2026.
This study demonstrates that FGFR‐targeted inhibition by AZD4547 in inflammatory cancer‐associated fibroblasts (iCAFs) intervenes into the tumor–stroma crosstalk. AZD4547 blocks IL‐1α–induced differentiation of pancreatic stellate cells into iCAFs, impairing iCAF‐driven tumor cell differentiation, migration, and M2 macrophage polarization. Consequently,
Ahmed M. R. H. Mostafa, Ahmed G. Hemdan, Franck Assayag, Jai Prakash   +3 more
wiley   +1 more source

Endocrine therapy and COVID-19 outcomes in women with breast cancer: a nationwide register- based matched cohort study. [PDF]

BMC Cancer
Schiza A, Digkas E, Papadopoulos F, Skalkidou A, Elenis E.   +4 more
europepmc   +1 more source

Evidence of APOE4‐related brain vulnerabilities in verbal memory systems in midlife women

Alzheimer's &Dementia, Volume 22, Issue 7, July 2026.
Abstract INTRODUCTION Women carrying the apolipoprotein E4 (APOE4) allele have a greater risk of Alzheimer's disease (AD) from ages 65‐75 years compared to men, yet the effects of APOE4 on cognitive and neuroimaging outcomes among midlife women remain poorly understood.
Katrina A. Wugalter, Rebecca C. Thurston, Minjie Wu, Howard J. Aizenstein, M. Ilyas Kamboh, Thomas K. Karikari, Pauline M. Maki   +6 more
wiley   +1 more source

Association Between Endocrine Therapy and Fracture Risk in Women with Breast Cancer in Germany-A Retrospective Cohort Study. [PDF]

Curr Oncol
Kostev K, Peters M, Sievert H, Kalder M.
europepmc   +1 more source

Pharmacogenetic CYP2B6 variants affect steroid hormone metabolism in human breast cancer cells

British Journal of Clinical Pharmacology, Volume 92, Issue 7, Page 2075-2084, July 2026.
Common genetic CYP2B6 variants correlate with adverse breast cancer outcome. The oestrogen metabolites estriol and 16‐epiestriol, which are formed downstream of CYP2B6‐catalysed 16α/β‐hydroxytestosterone, may be linked to elevated breast cancer risk and might increase due to the demonstrated CYP2B6 variants‐related metabolic shifts.
Marco Hoffmann, Julian Peter Müller, Stefan Düsterhöft, Sabrina Yamoune, Katja Susanne Just, Julia Carolin Stingl   +5 more
wiley   +1 more source

Management Strategies for Aromatase Inhibitor-Associated Musculoskeletal Symptoms and Their Impact on Treatment Persistence in Postmenopausal Breast Cancer: A Single-Center Retrospective Cohort Study. [PDF]

Int J Womens Health
Liang M, Yuan S, Xue Y, Li J, Chen C.
europepmc   +1 more source